US equities |
NVDA $235.36 ▲+1.95% MU $1,079.84 ▼-1.60% TSLA $371.25 ▲+4.84% SPCX $157.36 ▲+6.27% SNDK $1,724.24 ▼-3.55% AMD $630.50 ▲+2.40% STX $824.13 ▼-12.84% WDC $403.48 ▼-12.77%
FinancialContent

ProQR Therapeutics N.V. - Ordinary Shares (NQ:PRQR)

1.635 +0.005 (+0.31%)
Delayed Quote Updated: 12:48 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ProQR Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 Next >
News headline image
ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR to Participate in Upcoming Investor Conferences in September 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Second Quarter 2026 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces First Quarter 2026 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Year End 2025 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Planned Changes to Board Composition
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR to Participate in 8th Annual Evercore Healthcare Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Third Quarter 2025 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR to Participate in Upcoming Investor Conferences in October 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Second Quarter 2025 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Upcoming Presentation at RNA Editing Summit
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces First Quarter 2025 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Announces Year End 2024 Operating and Financial Results
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
From ProQR Therapeutics N.V.
Via GlobeNewswire
News headline image
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
From ProQR Therapeutics N.V.
Via GlobeNewswire
< Previous 1 2 3 Next >